Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Using Pharmacogenetics to Better Evaluate Naltrexone for Treating Stimulant Abuse

NCT03226223 is registered in ClinicalTrials.gov with New York State Psychiatric Institute as lead sponsor.

NCT NCT03226223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03226223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Using Pharmacogenetics to Better Evaluate Naltrexone for Treating Stimulant Abuse
Lead sponsor
New York State Psychiatric Institute
Phase
Phase 2
Overall status
Completed
Start date
September 15, 2016
Completion date
July 30, 2020
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

methamphetamine abuse, substance use disorders